NCT00346359View on ClinicalTrials.gov

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

November 30, 2007

Conditions
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

fludarabine phosphate

DRUG

methotrexate

DRUG

tacrolimus

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00346359 - Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer | Biotech Hunter | Biotech Hunter